1 |
Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407-14
|
2 |
King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006;48:223-32
DOI
ScienceOn
|
3 |
Van Muijen GN, Ruiter DJ, Warnaar SO. Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest 1987;57:359-69
|
4 |
Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985;121:235-47
|
5 |
Clover J, Oates J, Edwards C. Anti-cytokeratin5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997;31:140-3
DOI
ScienceOn
|
6 |
Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-21
DOI
ScienceOn
|
7 |
Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 2000;90:312-9
DOI
|
8 |
Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606
DOI
ScienceOn
|
9 |
Afify AM, Al-Khafaji BM, Paulino AF, Davila RM. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol 2002;10:178-82
DOI
|
10 |
Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996;192:137-47
DOI
ScienceOn
|
11 |
Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55-60
DOI
|
12 |
Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-46
DOI
|
13 |
Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-16
DOI
ScienceOn
|
14 |
Simsir A, Fetsch P, Abati A. Calretinin immunostaining in benign and malignant pleural effusions. Diagn Cytopathol 2001;24:149-52
DOI
ScienceOn
|
15 |
Kim BH. Utility of calretinin in distinction between benign reactive mesothelial and carcinoma cells in serous effusions. Kor J Cytopathol 2001;12:89-95
|
16 |
Chen LM, Lazcano O, Katzmann JA, Kimlinger TK, Li CY. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol 1998;109:712-21
DOI
|
17 |
Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-7
DOI
ScienceOn
|
18 |
Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10
DOI
ScienceOn
|
19 |
Atkinson BF. Atlas of diagnostic cytopathology. 2nd Ed. Philadelphia: W.B. Saunders. 2003; 205-23
|
20 |
Nagel H, Hemmerlein B, Ruschenburg I, Huppe K, Droese M. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology. Pathol Res Pract 1998;194:759-64
DOI
ScienceOn
|
21 |
Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-33
DOI
ScienceOn
|
22 |
Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-62
DOI
ScienceOn
|
23 |
Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51
DOI
ScienceOn
|
24 |
Kang DY, Son JH. The utility of desmin in differentiation between reactive mesothelial cells, malignant mesothelioma cells and metastatic adenocarcinoma cells in serous effusions. Kor J Cytopathol 2003;14: suppl 1. 45. Abstr
DOI
ScienceOn
|
25 |
Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004;12:122-6
|
26 |
Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7
DOI
ScienceOn
|
27 |
Truong LD, Rangdaeng S, Cagle P, Ro JY, Hawkins H, Font RL. The diagnostic utility of desmin. A study of 584 cases and review of the literature. Am J Clin Pathol 1990; 93:305-14
DOI
|
28 |
Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231-8
DOI
ScienceOn
|
29 |
Hecht JL, Lee BH, Pinkus JL, Pinkus GS. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer 2002;96:105-9
DOI
|
30 |
Roberts F, McCall AE, Burnett RA. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. J Clin Pathol 2001;54:766-70
DOI
ScienceOn
|
31 |
Brockstedt U, Gulyas M, Dobra K, Dejmek A, Hjerpe A. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;114:203-9
DOI
ScienceOn
|
32 |
Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61-6
DOI
ScienceOn
|
33 |
Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-20
|
34 |
Gill SA, Meier PA, Kendall BS. Use of desmin immunohistochemistry to distinguish between mesothelial cells and carcinoma in serous fluid cell block preparations. Acta Cytol 2000;44:976-80
DOI
ScienceOn
|
35 |
Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001;116:709-15
DOI
ScienceOn
|
36 |
Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-5
DOI
ScienceOn
|
37 |
Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct Pathol 1996;20:293-325
DOI
|
38 |
Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12
DOI
ScienceOn
|
39 |
Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50
DOI
ScienceOn
|
40 |
Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150-8
DOI
ScienceOn
|
41 |
Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-12
DOI
ScienceOn
|
42 |
Moll R, Dhouailly D, Sun TT. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;58:129-45
DOI
|
43 |
Chhieng DC, Yee H, Schaefer D, et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000;90:194-200
DOI
|
44 |
Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372-80
DOI
|
45 |
Barberis MC, Faleri M, Veronese S, Casadio C, Viale G. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997;41:1757-61
DOI
ScienceOn
|
46 |
Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-56
|
47 |
Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-19
DOI
ScienceOn
|
48 |
Gonzalez-Lois C, Ballestin C, Sotelo MT, Lopez-Rios F, Garcia-Prats MD, Villena V. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-34
DOI
ScienceOn
|